What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2025-03-28 compared with 2024-04-10 · 191 added, 931 removed, 1 unchanged (100% of the section changed)

We are an early commercial-stage life sciences instrumentation and

research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics”

We leverage our expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute

major advancements to scientific research and development by accelerating one’s understanding of the molecular mechanisms of disease

and fundamental biological processes.

We believe our proprietary sequencing technology platform has critical advantages over existing

NGS (Next Generation Sequencing) technologies, particularly for emerging applications in the research and development of biomarker discovery,

epigenetics, nucleotide chemistry, forensics, and cell-free nucleic acid analysis.

Our mission is to empower researchers with improved

genetic tools that enable scientists and physicians to better understand the molecular mechanisms of disease and the underlying biological

This knowledge is essential to the continued development of new breakthroughs in genomic medicine that address the critical concerns

involved with today’s precision medicine.

Our single molecule technology enables researchers to identify and

synthesize DNA or RNA strands, irrespective of abundance, in a biological sample and is capable of analyzing billions of molecules in

parallel, which positions us as both competitive and complementary with other NGS platforms.

We believe our technology advantage is a

simplified method of quantifying DNA and RNA molecules at single molecule resolution because our platform does not require the routine

PCR amplification and library preparation and ligation steps required by most NGS systems, thereby avoiding systematic bias and consequential

additional costs.

Our current sequencing platform offers advantages, such as the ability of certain samples to reveal previously unknown

molecular profiles by directly detecting single molecules with little to no manipulation of the original sample.

Our tSMS platform then

generates data that is highly accurate and creates reproducible molecular profiles, often providing researchers with new insights into

the biology being researched.

As supported by multiple peer-reviewed research publications, our tSMS technology platform has assisted

medical researchers in uncovering potentially significant DNA and RNA biomarkers for the early detection of diseases.

Our strategy is to integrate the tSMS platform with the development

of novel applications across multiple market segments, and to generate revenue through sales of partnership-specific systems and related

flow cells and reagents, which we refer to as “sequencing kits”, research services and research grants.

We do not offer or

sell any products that are founded upon or incorporate our tSMS platform directly to healthcare professionals or consumers.

To strengthen

our market position, we strive to build and control intellectual property around the instruments, sequencing kits and methods that enable

these applications to strengthen our market position.

Integral to this strategy will be to work with existing customers in developing

new instruments optimized for specific assay and chemistry performance in order to support a wide array of applications.

Our target customers

are consumers of NGS products and services engaged in research activities and the development of new or improved products, such as academic

and government institutions, hospitals and medical centers, pharmaceutical and biotechnology companies, and non-profit research organizations.

Under our current operating model, we expect the revenue we generate

from a specific customer to scale as our partnership or collaboration with such customer matures and the intellectual property founded

on our tSMS platform is developed and sold by such customer.

Initially, our customer-specific revenue is typically dependent on the funding

of, or research grants obtained by, our partners and their ability to develop novel products.

During the early stages of our partnerships

or collaborations, we generally derive revenue from research services, grants, and the sale of customized instruments and sequencing kits

as intellectual property is developed.

Over the longer term, however, we expect to generate increasing revenues from our customers from

the sale of application-specific assays or tests that are developed on our platform and for which we will receive royalties, a revenue

split or other renumeration for the use of our platform or jointly-developed intellectual property.

Background on Genetic Sequencing

Genetic inheritance in living systems is conveyed through a naturally

occurring information storage system known as deoxyribonucleic acid, or DNA.

DNA stores information in linear chains of chemical bases

known as adenine (“A”), cytosine (“C”), guanine (“G”) and thymine (“T”).

Inside living

cells, these chains usually exist in pairs bound together in a double helix by complementary base pairs.

A “genome” is an

organism’s complete set of DNA, which for humans consists of approximately three billion DNA base pairs.

Ribonucleic acid, or RNA,

is a molecule used by organisms to convey genetic information.

A “transcriptome” is an organism’s complete set of RNA

molecules at an active cellular state and includes both protein coding and noncoding RNA transcripts.

Genetic sequencing is the process of determining the order of nucleotide

bases (A, C, G, or T) in a sample.

This consists of three phases:

sample preparation, physical sequencing and analysis.

Generally, the

first step of sample preparation is either to shear the target genome into multiple small fragments or, depending on the amount of sample

DNA or RNA available, amplify the target region using a variety of molecular methods.

In the physical sequencing phase, the individual

bases in each fragment are identified in order, creating individual sequence reads.

The number of individual bases identified contiguously

is defined as “ read length .” The sequencing throughput is generally defined as the product of the number of individual

sequence reads and the average read length of the sequence reads.

In the analysis phase, bioinformatics software is used to align overlapping

reads, which allows the original genome to be assembled into contiguous sequence.

Studying genomes and transcriptomes helps scientists understand the

inheritance of biological characteristics, developmental biology and normal and disease states of cells and organisms.

Genetic variation

accounts for many of the differences between individuals, such as eye color and blood group, and also affects a person’s susceptibility

to certain diseases such as cancer, heart disease or diabetes.

Genetic variation can also determine a person’s response to drug

A trend in healthcare is towards ‘personalized medicine’

to enable more accurate diagnosis and treatment through better understanding of each individual patient’s disease.

We believe that

a greater understanding of the genome will lead to this new healthcare paradigm where diseases are understood at the molecular level,

allowing patients to be diagnosed according to genetic information, in many instances earlier and more accurately, and be treated with

drugs designed to work on specific molecular targets.

The goal is to offer precision-personalized medicine that will identify disease

earlier, reduce healthcare costs, and enable more appropriate and effective treatment for better outcomes and quality of life.

this has largely been done through genomic testing, which provides information about a patient’s predisposition to disease or likely

response to medication, due to each individual’s unique constellation of genes.

However, DNA testing is, in most cases, a static

readout that does not change through a patient’s lifetime or disease course.

It does not provide information about the patient’s

current health status.

An increasing number of researchers, however, now believe the transcriptome provides dynamic information about

the current state of the body that can be used to assess health, to detect early signs of disease and to enable physicians to select the

appropriate treatment, monitor response to treatment and detect unwanted side effects.

Cell-free Nucleic Acids as Disease Biomarkers:

of the DNA and RNA in the body are inside the cells, but a small amount of nucleic acids is also found in biological fluids such as blood,

saliva and urine.

This material is generally referred to as cell-free DNA (“cfDNA”) and cell-free RNA (“cfRNA”).

Analysis of these free-floating molecules can lead to multiple applications such as early disease detection, drug selection and treatment

For example, large amounts of cell-free DNA material might indicate a bacterial infection or sepsis in very early stages.

Cell-free DNA is typically derived from chromatin as intact nucleosomes, or histone-bound DNA, which can be analyzed in addition to solely

assessing DNA.

Another such example is cfRNA analysis for detection, diagnosis and monitoring of malignant diseases such as cancer.

cfRNA transcripts are differentially expressed between normal and cancerous tissues.

These transcripts can be used as a reliable biomarker

for cancer screening and diagnostic applications.

Analysis of cfRNA can be used to measure dynamic changes in the gene expression, allow

oncologists to evaluate disease status, predict outcomes from anti-tumoral therapies and monitor the disease after treatment.

Sequencing Technologies:

There are different sequencing technologies

available for sequencing genetic material, each producing the sequence data in a unique format.

Some of the technologies produce millions

of sequence reads with a very short-read length, generally less than 300 nucleotide bases.

These technologies are generally referred as

short-read NGS platforms.

Other technologies produce several thousand sequence reads of a very long-read length, generally more than 1,000

nucleotide bases.

These technologies are generally referred as long-read NGS platforms.

Both, the short- as well as long-read NGS technologies

have their advantages in various settings.

For de novo assembly of genomes and long RNA transcripts, the long contiguous

reads from the long-read NGS technologies are preferred.

Generally, short-reads can be used to further fill in gaps in the data from longer

read technologies.

For molecular counting application, a large number of independent reads from short-read NGS technologies are preferred.

RNA quantitation typically occurs after converting extracted RNA molecules into cDNA fragments using commercially available reverse transcriptase

as part of that process.

This approach, within which there are a variety of methods, is loosely defined as RNA sequencing or “RNA-Seq”.

Different genes are present in varying amounts in biological samples, and the success of the technique is highly dependent on the dynamic

range of the detection technology.

Market Opportunity

The market for our products and services is segmented into two major

categories, DNA NGS and RNA NGS, which, according to The Insight Partners, accounted for a combined addressable market opportunity of

approximately $1.03 billion in 2019 that is projected to grow to $5.26 billion by 2025 at a CAGR of 31.3%.

DNA NGS market opportunity:

to The Insight Partners DNA NGS Market Report 2019 , the global DNA NGS market is projected to grow from $6.82 billion in 2019 to

$22.72 billion in 2025 at a CAGR of 22.2% from 2019 to 2025.

Our customers in the DNA NGS market largely consist of academic and research

institutes and forensic labs.

Collectively, academic and research institutes and forensic labs, pathology labs and diagnostic centers

represent a projected 58.4% of the end-user market share in 2019.

The versatility of the tSMS platform can be applied across our near-term

target segments of drug discovery, precision medicine and other novel applications.

We intend to focus our commercialization efforts on

academic and research institutes and forensic labs in North America and Europe, and will eventually expand our efforts to the Asia Pacific

North America and Europe represented 69.9% of the global market in 2019.

Our targeted end users, applications and regions for

DNA NGS offered an addressable market opportunity of $0.74 billion in 2019 that is projected to grow to $4.10 billion in 2025 at a CAGR

RNA NGS market opportunity:

to The Insight Partners NGS-based RNA Seq.

Market Report 2019 , the global RNA NGS market is projected to grow from $1.63 billion

in 2019 to $4.96 billion in 2025 at a CAGR of 20.4%.

We intend to leverage our simplified workflow, which reduces bias and misrepresentation

caused by various enzymatic steps that other technologies utilize, to accelerate market penetration.

The RNA NGS market can be segmented

by products and services, end users, applications and sequencing technologies.

Research and academic centers, pharmaceutical and biotech

companies, pathology labs, forensic labs and diagnostic centers represented a projected 76.7% share of the end users in 2019.

Our simplified

and mature RNA sequencing approach will facilitate a broad application pool across diagnostics, drug discovery, precision medicine and

biomarker discovery field.

We will offer RNA sequencing platform and sequencing kits, sequencing services and data analysis products featuring

our tSMS technology to such potential customers.

Furthermore, we intend to focus on commercialization of our products in North America,

Europe and Asia Pacific regions, which collectively accounted for 81.2% of the global market geographically in 2019.

Our targeted end

users, applications and regions for RNS NGS offered an addressable market opportunity of $0.29 billion in 2019 that is projected to grow

to $1.16 billion in 2025 at a CAGR of 26.2%.

Limitations of Existing Technologies

There are multiple short-read and long-read NGS technologies available

in the market that partially address the need for accurate and sensitive analysis of genetic information.

These technologies can further

be classified based on the resolution of the technology as single-molecule sequencing technology and amplification-based technologies.

Most single-molecule sequencing technologies do not require amplification, though many of the long-read technologies still require complex

sample manipulation prior to sequencing.

This is especially true for sequencing of RNA molecules.

Over the past two decades, researchers

and clinicians have used these technologies to gain a deeper understanding of nucleic acids, to study biomarkers associated with disease,

to identify molecules for new drug discovery, to create novel applications for early screening and diagnosis, and more recently to create

genome-editing techniques.

While researchers are making progress on various fronts by utilizing a combination of these technologies, there

remains a wide gap between the needs of the research community and the capabilities of existing sequencing tools.

This gap is hindering

the advancement of scientific research.

The inherent limitations of current technologies are summarized below:

Short-read NGS technology typically requires a large number of DNA molecules during the sequencing process.

To generate enough DNA molecules, an amplification step is required during sample preparation.

This amplification process can introduce

errors known as amplification bias.

The effect of this bias is that resulting copies are not uniformly representative of the original

template DNA, causing skewed data representation in the final results.

Lower sensitivity :

In cases where the

original template DNA contains regions of relatively high G-C content or relatively high A-T content, the amplification process

tends to under-represent these regions.

As a result, these regions, which may contain entire genes, can be completely missed.

non-linear nature of the amplification thus limits its ability to detect subtle changes in the genetic signature.

Inefficient library preparation :

our competitors use systems requiring multi-step sample preparation protocols to prepare sample libraries before sequencing.

library preparation technique is inefficient, capturing only a fraction of the informative input material.

The process selectively

captures the molecules that are present in large quantities while losing lower frequency molecules, thus not producing a true

representation of the input material.

The library preparation protocol limits the minimal amount of input sample.

preparation steps also add significant burden on the sample preparation.

Inadequate throughput :

Applications such

as transcriptome profiling, gene expression and biomarker discovery require accurate quantification of data.

The long-read single

molecule technologies fall short due to the smaller number of strand throughput required to substantiate the presence or absence of

a biomarker in a specific sample.

The short-read amplification technology is limited due to a skewed data representation caused by

the non-linear amplification bias present in the workflow.

Our Technology Solution

Our tSMS platform offers a single molecule solution for DNA and RNA

sequencing by performing detection of nucleic acids without the need for complex sample manipulation.

Researchers using our platform can

analyze many billions of single molecules in a single experiment and still generate highly accurate and reproducible data.

our technology’s critical advantage over other technologies is because our platform does not require the routine library preparation

steps, such as PCR amplification and ligation, necessary for use with most NGS systems, thereby avoiding systematic amplification bias.

RNA sequencing on our platform detects transcripts regardless of abundance and with high accuracy in quantifying gene expression changes

associated with certain disease as well as detecting subtle changes in RNA transcript levels that are undetectable with other methods.

Our single molecule platform is unique because it combines a proprietary

fluorescence-based optical detection apparatus with a precision microfluidics and thermal control system to perform sequencing-by-synthesis,

as illustrated in Figure 1 below.

tSMS Technology Workflow

Our platform typically derives sequencing information directly from

the sample itself, not a copy of the sample.

It does not require amplification at any stage of the process and offers simple, straightforward

sample preparation protocols.

The technology uses a single-stranded DNA and RNA material with lengths that range from less than 20 bases

to more than 1000 bases as an input.

The platform then captures the material on a glass surface and uses a patented fluorescence-based

optical detection apparatus combined with a precision microfluidics system to perform a sequencing-by-synthesis reaction on the input

The single molecule fluorescence signal from millions of individual

strands is captured by images using a high-sensitivity camera during multiple cycles of nucleotide incorporation.

Our powerful image analysis

system processes these images to produce the sequence data as an output.

The output data contains millions of individual unique sequences

with the average read length of between 35–60 nucleotide bases, with a range of 20–100 nucleotide bases.

This length is sufficient

to allow unambiguous identification of the origin of each sequence.

Our system still requires isolation and preparation of DNA or RNA samples;

however, our system is adaptable to most purification and preparation kits and techniques that are currently available in the market and

no additional or special steps are required to prepare the samples for sequencing.

The single molecule resolution of the sequence data in association

with a sub-100 nucleotide base read length positions our platform as the only short-read single molecule sequencer commercially available

in the market.

The amplification-based short-read technologies are already helping the scientists in the fields of research, diagnostics

and therapeutics.

By giving the short-read technology the power of single molecule resolution, we believe our tSMS technology offers critical

advantages over existing technologies, including:

Minimal Sample Preparation .

Our tSMS platform offers a simple sample preparation process.

The DNA strands are cut in shorter sizes, converted into single strands, and then tagged with a universal surface capture primer.

By avoiding the complex multi-step library preparation method, the sample integrity is preserved, and the bias and errors in the sequence data output exhibited by other methods are avoided.

The simplicity of our sample preparation workflow and its effect on the output data variance, compared to NGS data produced by an Illumina system, is illustrated in Figure 2 below.

[ van den Oever et.

(Clinical Chemistry, April 2012) ].

tSMS vs Amplification-based Technologies

Greater Sensitivity .

Our tSMS platform offers a high level of sensitivity as each strand is identified and synthesized irrespective of its abundance in the sample.

In the existing amplification-based technologies, low expressing transcripts are typically masked due to preferences and may be missed or have their numbers minimized in the final data analysis.

The simplified sample preparation along with single molecule resolution facilitates the unbiased, proportionate representation of input sample, even of the low expressing transcripts and constructs.

This allows for obtaining more accurate information earlier (for potential clinical treatments or decisions to be made sooner).

Figure 3 below illustrates that the tSMS platform identified low-expression transcripts missed by the standard PCR-based methodology when using Illumina.

The lowest expressed quartile of transcripts was detected with our tSMS technology at a 7.10x rate compared to a leading NGS platform [Sam LT, Lipson D, Raz T, et al.

A Comparison of Single Molecule and Amplification Based Sequencing of Cancer Transcriptomes.

tSMS Improves Detection of Lowest

Expressed Genes

High Accuracy .

Our tSMS platform provides an accurate set of data and results as well as a broader range of molecules to be evaluated.

The ability to count each individual molecule, combined with simplified sample preparation and greater sample sensitivity, yields an accurate quantitative representation of sample in the final data.

Our technology has been demonstrated to produce robust accurate short-reads for a variety of applications.

Seamless Flexibility .

Our tSMS platform provides flexibility in two main aspects — throughput and applications.

The tSMS platform has the ability to scale the throughput across a range of small to large projects.

The programmable instrument workflow and modular design of sequencing kits provide flexibility to choose the sample coverage and read length required for the final data.

The simplified sample preparation allows for analysis of any genetic material that can be attached to a glass surface.

Our Gene Sequencing Methodology

The patented tSMS technology is the essence of our tSMS platform.

gene sequencing methodology takes genetic material as input and produces sequence data as an output through sequentially processing the

following five major steps.

preparation :

A double helix strand is cut into fragments of 100–200 nucleotides in length.

In the case of cfDNA and

cfRNA material, this step is not necessary as cell-free strands are generally short and fit the profile of the input material.

fragments are then denatured to a single strand, and a poly-A universal priming sequence is added to one end of each strand as shown

in the following figure.

Sample loading :

The strands are

hybridized in a flow cell with billions of universal Oligo T capture sites mobilized on the flow cell surface.

The tSMS method

typically utilizes a dT50 primer to initiate sequencing from a 3’ poly-A tail, although other capture primers may be used to

increase the specificity of sample hybridization.

Template registration :

Once hybridized,

a “Fill & Lock” step fills up the rest of the open bases from the poly-A tail followed by the addition of

fluorescently labelled nucleotides to the start of the strand.

A laser illuminates the flow cell and the camera records the location

of each captured sample strand.

The flow cell is moved in sequential steps to allow the camera to cover its entire active area.

dye molecules are then cleaved and washed away.

tSMS sequencing-by-synthesis :

DNA polymerase enzyme and the

first of the four types of novel fluorescently labelled nucleotides are added.

If the nucleotide is complementary to the next base

in the template strand, the polymerase will add it to the primer strand.

The nucleotides are designed to inhibit the polymerase from

incorporating more than one base at a time on the same strand.

Excess polymerase and

unincorporated nucleotides are then washed away.

This step ensures that only the incorporated nucleotides are available for

fluorescence imaging.

The narrow bandwidth laser

illuminates the flow cell surface to excite the fluorescently labelled nucleotides.

The camera records the locations where

fluorescently labelled nucleotides were added.

The fluorescent dye molecules

are then cleaved from the labelled nucleotides and washed away.

This step ensures that these molecules are fluoresced only for that

particular nucleotide addition cycle.

The process is repeated with each of the four types of labelled nucleotides

until a desired sequence length is reached.

As an example, repeating this cycle 120 times adds an average of more than 33 nucleotides

to the primer strand.

In sequencing, this is known as the “read length.”

The image analysis computer analyzes the series of images from each cycle and determines the sequence of bases in

the template strand.

The sequence is “read” by correlating the position of a fluorescent molecule in its vertical track with

the knowledge of which base was added at that cycle.

The sequence data is packaged in standard sequencing data formats for further bioinformatics

Our True Single Molecule Sequencer (tSMS)

Described above is our gene sequencing methodology using our tSMS single

molecule sequencing platform.

It combines a simplified operation with powerful capabilities to directly sequence original samples of RNA

and DNA consisting of major components:

The flow cells and reagents are the major components of a sequencing kit that the instrument needs at the start

of every new run.

The custom flow cell features 25 discrete flow channels, and each channel of the flow cell has millions of capture

probes deposited on the cover glass.

The sequencing samples are loaded into the flow cell channels using the sample loader.

The sequencing

run can sequence up to two flow cells in a single run.

The reagent kit for the sequencing run consists of custom pre-packaged bottles

that store proprietary tSMS chemistry reagents and wash buffers for the system.

All of the flow cells and reagent kits are barcoded,

so the sequencer can scan and store the barcodes as a part of the experiment setup procedure.

Sample Loader :

The sample loader

facilitates loading the billions of tailed single strands onto the glass surface of the standard 25 channel flow cell.

temperature-controlled chamber improves the hybridization efficiency and houses a mechanism to hold a standard flow cell used in the

The proprietary sample loading block design helps to keep the transfer volume to near zero microliter, while the system

offers precision control of loading the sample in 25 discrete channels without any cross-contamination.

The input material volume

for the sample loader can be as little as 20 microliters.

tSMS Sequencer :

The sequencer accepts up

to two flow cells for a sequencing run, allowing sequencing of up to 50 individual samples in a single run.

The benchtop sequencer

is a fully-automated device that combines a Total Internal Reflection Fluorescence (TIRF) microscopy technique with a

high-precision, temperature-controlled microfluidics system.

The microfluidics system houses the reagent kit required to perform

tSMS chemistry, and uses high-precision pumps and valves to formulate the chemistry just-in-time for delivery to the flow cell

chamber during each chemistry cycle.

The two-flow cell design maximizes the machine utilization by performing the chemistry cycle on

one flow cell while the other flow cell is going through the imaging cycle, and vice-a versa.

The flow cells are mounted on a

high-speed, high-accuracy multi-axis stage that moves the flow cell along the channel with nanometer grade precision.

The high-power

optics system consists of a narrow bandwidth laser to provide the excitation signal, while the high-fidelity imaging system uses a

highly sensitive camera for capturing the single molecule signal emitted by the fluorophores.

All of these subsystem operations are

integrated and controlled by an on-board computer in a completely automated fashion over the course of the run.

A simple touch

screen based graphical user interface walks the user through an intuitive run setup.

A typical run on the sequencer captures three

to six million images containing information about billions of individual single molecules in the strands.

Image Analysis Engine :

analysis engine processes the images captured by the sequencer camera, aligns them with the template image at individual position,

and creates the sequence data file to be used for further bioinformatics analysis.

It features a high-power CPU array with large

storage capacity hard drives specifically designed for intensive image analysis and storage purposes.

The image analysis engine runs

parallel to the camera, processing the images as soon as the camera starts imaging the flow cell.

The image analysis engine software

monitors the instrument status and automatically uploads the sequence data at the end of the run at a user-configurable network

The instrument has a web-based interface for remote monitoring that

updates the key sequencing metrics and the instrument status in real time.

The database system of the instrument stores the detailed logs

for both record keeping and troubleshooting purposes.

Markets for Our Technology

The initial target market for our instruments and research services

has been the life sciences research and development market where we provide solutions for a variety of applications, including biomarker

discovery and diagnostic assay developments.

This market includes laboratories associated with universities, scientific research centers,

government institutions, and biotechnology and pharmaceutical companies.

Our tSMS technology platform produces data with potential diagnostic

implications, detecting biomarkers for cardiovascular diseases and various types of cancer, and offers an optimal solution for use in

sequencing applications.

We anticipate using these strengths to capture a portion of the growing multi-billion dollar NGS market.

to build and control intellectual property around the instruments, sequencing kits and methods that enable these applications to strengthen

our market position.

The major consumers of the NGS include academic and government institutes, hospitals and medical centers, pharmaceutical

and biotechnology companies, non-profit research organizations and agrigenomics organizations.

Introduction of new technologies and products, while positive to the

overall development of these markets, may result in greater competition for the limited financial resources available.

There are a number

of emerging markets for sequencing-based technologies that represent significant potential opportunities for us, such as but not limited

sciences research and development:

NGS technologies are accelerating the discovery and development of more effective

The complex nature of biological pathways, disease mechanisms and multiple drug targets requires an accurate, unbiased, and

sensitive molecular counting platform.

Single molecule sequencing, with its unparalleled quantitative accuracy in large-scale expression

profiling could enable high-throughput screening of promising drug leads.

During clinical trials, our technology could potentially be

used for companion diagnostics to generate individual genetic profiles that can provide valuable information on likely response to therapy,

toxicology or risk of adverse events.

The tSMS platform may also enable more precise selection of patient pools and individualization

● Liquid biopsy:

biopsy is emerging as a simple and non-invasive alternative to the traditional tissue biopsy approach for disease screening and

A simple draw of blood contains millions of tiny fragments of cell-free DNA/RNA material with lengths on the order of

100–200bp, which carry informative signatures of cancer and other life-threatening diseases even in a very early stage of the

disease progression.

With its quantitative accuracy, simple sample preparation methodology, and its ability to accurately sequence

fragmented short molecules, our single molecule sequencing offers an excellent solution for liquid biopsy.

Infectious diseases are disorders caused by bacteria, viruses and fungi.

These organisms contain DNA and RNA that act

as infectious agents to transmit disease from person to person, by insect or animal, or through food and environmental means.

The detection

and sequencing of the DNA and RNA from pathogens provides medically actionable information for diagnosis, treatment and monitoring of

Accurate sequence information could also help to predict drug resistance.

Our amplification and ligation free sequencing method allows us to identify subtle changes in the RNA transcript

levels that are undetectable with other methods presumably due to bias and loss of low-level transcripts inherent to the other technologies.

The power of our tSMS technology can help to address the large unmet need for biomarker discovery to diagnose diseases such as cardiovascular

diseases and cancer at very early stages.

The potential of our technology for bio-marker discovery is illustrated in Figure 4 below,

where tSMS RNA-seq was utilized to identify RNA-based gene expression changes associated with ADHD [McCaffrey TA, St Laurent G 3 rd ,

Shtokalo D, et al.

Biomarker Discovery in Attention Deficit Hyperactivity Disorder:

RNA Sequencing of Whole Blood in Discordant Twin

and Case-controlled Cohorts.

BMC Med Genomics .

Further studies offer the opportunity for validating future diagnostics

applications.

Biomarker Discovery in ADHD using tSMS

Microbiome analysis:

communities in and on the body show uniform bacterial diversity in healthy individuals.

Drugs and diet can disrupt the microbial

diversity, and thereby can affect disease progression and treatment efficacy.

Our technology can accurately quantify the gene

signature for all bacteria present and capture a real-time snapshot of the microbiome.

This data can be used by physicians for

disease treatment by applying methods to encourage growth of beneficial microbes and eliminate harmful microbes.

These examples of emerging markets for sequencing-based technologies

represent significant potential opportunities for us.

The development of these markets is subject to variability driven by ongoing changes

in the competitive landscape, evolving regulatory requirements, government funding of research and development activities, and macroeconomic

Given the ability of the tSMS platform to sequence nucleic acid fragments as well as to detect post-translational modifications

within larger chromatin molecules, we believe our technology is uniquely positioned to produce data from molecules at both ends of the

single molecule nucleic acid spectrum.

This concept, and the technology leaders for each single molecule market segment, is illustrated

in Figure 5 below, with our potential applications highlighted in blue font.

Illustrative Single Molecule Nucleic

Acid Landscape

Our Business Strategy

Our mission is to empower researchers with improved genetic tools that

enable scientists and physicians to better understand the molecular mechanisms of disease and the underlying biological systems.

knowledge is essential to the continued development of new approaches and breakthroughs in genomic medicine that address critical concerns

relating to today’s precision medicine efforts.

Our strategy is to integrate our tSMS platform with the development

of novel applications across multiple market segments, and to generate revenue through partnership-specific systems and sequencing kit

sales, research services and research grants.

We strive to build and control intellectual property around the instruments, sequencing

kits and methods that enable these applications to strengthen our market position.

Integral to this strategy will be to work with existing

customers in developing new instruments optimized for specific assay and chemistry performance in order to support a wide array of applications.

Our target customers are consumers of NGS products and services engaged

in research activities and the development of new or improved products, such as academic and government institutions, hospitals and medical

centers, pharmaceutical and biotechnology companies, and non-profit research organizations.

We have generated only nominal revenues to date from our current operating

model and we do not expect our revenues to scale significantly until one or more of our customers or third-party partners or collaborators

has developed application-specific assays or tests for which our platform serves as a foundation.

Over the longer term, we expect to generate

revenues from our customers, partners and collaborators through a combination of product sales, research services and research grants.

We plan to expand these revenues from recurring and prospective clients by the following key strategies:

Provide the scientific community with a combination of research services and instrumentation to serve markets that we believe are inadequately addressed by existing technologies.

Continue to innovate and develop new aspects of our products and technology, applications and instrumentation through scientific collaborations, including grants.

Leverage our expertise and the broad applicability of our tSMS platform to grow into new markets through strategic collaborations, partnerships, existing data sets, and customers.

Maintain a strong culture and network of technical resources while continuously attracting new talent to build an industry leading single molecule solutions company.

Our Customers and Collaborators

Our customer base is focused on academic research, biomarker discovery,

and molecular diagnostic product development.

These customers over the years have produced scientific achievements through collaborative

research efforts.

Our current customers are early adopters of genomics technology including tSMS.

A significant portion of the funding

for these developing technologies has historically come from research grants provided by government agencies and non-profit research centers.

We often collaborate with customers to drive innovation in the field of genomic sciences through grant funded research activities.

key collaborators and our current activities are highlighted below:

Department of Justice’s Federal Bureau of Investigation

In February 2023, we announced the establishment of a two-year Cooperative

Research and Development Agreement (CRADA) with the FBI.

Under this CRADA, SeqLL and the FBI Laboratory Division (FBI LD) will seek to

evaluate and determine the forensic capabilities of direct RNA sequencing using our tSMS platform.

The FBI LD and SeqLL will collaborate

with a goal of producing an assay for forensic body fluid identification, without compromising traditional STR or DNA sequence analysis.

This agreement is among the first times the FBI is utilizing the CRADA mechanism to further develop laboratory capabilities.

CRADAs enable

the sharing of resources and expertise for collaborative research that advances the FBI mission.

Body fluid identification can provide

investigative context and have probative value.

Weizmann Institute of Science

In partnership with the laboratory of Efrat Shema, Ph.D., we have

recently developed and applied innovative single-molecule technologies to gain a deeper understanding of chromatin regulation.

working to establish robust single-molecule systems for genome-wide profiling of combinatorial chromatin and DNA modifications, as well

as development of novel therapeutic and diagnostic tools.

We published multiple manuscripts in 2022, including “H3-K27M-mutant

nucleosomes interact with MLLI to shape the glioma epigenetic landscape” in Cell Reports and “Multiplexed, single-molecule,

epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics” in “Nature Biotechnology.

We have provided the

Weizmann Institute with access to prototype sequencing systems, sequencing kits, and sample preparation methodologies.

Future Products

We expect to partner or collaborate with biotech and pharma companies

to develop a clinical-grade diagnostic tests.

We intend for our partners to commercialize these diagnostic or forensic tests for applications

liquid biopsy for oncology applications, microbiome analysis, and transcriptome-based diagnostics for cardiovascular disease, infectious

disease and others.

We will look to increase industry visibility and expand our reach globally for both sequencing services and instrument

sales through strategic customer relationships and partnerships with larger organizations that can increase global support, supply and

distribution.

Through those partnerships, we plan to also identify new, high-value, cutting-edge applications that are uniquely enabled

by our tSMS platform.

As our partners or collaborators expand their product lines to address

the diagnosis of disease, regulation by governmental authorities in the United States will become an increasingly significant factor

in development, testing, production and marketing.

Products developed for the diagnostics market, depending on their intended use, may

be regulated as in vitro diagnostics by the FDA.

Each medical device to be distributed commercially in the United States will likely

require either 510(k) clearance or approval of a pre-market approval application (PMA) from the FDA prior to marketing the device for

in-vitro diagnostic use.

Clinical trials related to regulatory submissions may take years to complete and represent a significant expense.

The 510(k) clearance pathway usually takes from three to 12 months, but can take longer.

The PMA pathway is more costly, lengthy and uncertain,

and can take from one to three years, or longer.

We have not sought FDA approval of our sequencers because to-date we

have marketed them for research purposes and not for clinical diagnostics.

Through our partners or collaborators, we will likely need

to assist in pursuing regulatory approvals from the FDA when they attempt to enter the diagnostics market, which is expensive, involves

a high degree of risk and there is no assurance that we will be able to develop a commercially viable product.

Even if the products under

development are authorized and approved by the FDA, our partners or collaborators must still meet the challenges of successful marketing,

distribution and customer acceptance.

Marketing, Sales, Service and Support

Our business model is focused on offering our customers and collaborators

access to our tSMS technology in order to drive comprehensive and reliable solutions that enhance acceptance, customer loyalty and confidence,

revenue growth and shareholder value.

We plan to focus on addressing specific markets for which there are not currently adequate solutions.

This will require education and demonstration of added value by helping customers and collaborators meet program timelines, providing

data that supports their programs, and implementing custom solutions to meet each customer’s specific objectives.

We currently generate

revenue by selling to existing customers and through collaborative, research-focused efforts that create additional sales and growth opportunities.

To achieve recurring growth for our research services revenues and

drive new value creation, we are implementing the following initiatives to increase market awareness of the tSMS platform:

Defining our value proposition in terms of commercial value and solution to customer needs, as related to platform flexibility, speed to solution, and comprehensive quality of the genetic information provided.

Creating new literature that highlights our technology, instruments and capabilities.

This includes brochures, white papers, application notes, case studies, and solution’s value proposition marketing material.

Implementing new customer facing programs including trade show participation, posters and presentations to showcase the solutions for commercial needs, and attending scientific conferences that publish the research data from the tSMS platform.

Expanding visibility in segment verticals with segment organization participation and by creating integrated training and education programs as a part of instrument sales and the training process.

Furthering research collaborations with key opinion leaders to address critical, high potential needs and publish the findings in the peer-reviewed scientific journals.

We believe this approach maximizes value to our customers and shareholders

by supporting the largest possible number of customers.

Manufacturing

We have the capability to manufacture the required sequencing kits

and instrumentation at our own manufacturing facility.

We believe manufacturing all system components internally results in greater trade

secret protection for our proprietary formulations and mechanics, a higher degree of customer satisfaction in our research business, and

lower production costs.

In the future, we may outsource some of the non-proprietary reagents and basic instrumentation sub-assemblies

for parallel inventory production ramp-ups.

Relationships to various contract manufacturing organizations have already been established

and we believe several are prepared to provide these services once production demand exceeds internal capacity.

Our current manufacturing staff is comprised of a team of engineers

and technicians each having more than 10 years of experience with the tSMS product line.

The manufacturing team has deep experience

with the tSMS platform and has the ability to adapt to future needs on both the hardware and sequencing kits.

In addition, this group

has experience in FDA product clearance and working in an FDA regulated environment.

The team has been involved in manufacturing commercially

available tSMS instruments since its original design and subsequent production in 2008.

We are planning to establish a controlled manufacturing process and

environment, and to implement standards according to the International Organization for Standardization (ISO), 5S lean manufacturing methodology,

and other lean techniques.

We also plan to create work cells for efficiency and material control for both sequencing kits and instrumentation.

Implementation of quality assurance in manufacturing documentation and processes is one of our top priorities as we continue the path

toward releasing a clinical grade tSMS sequencer that is compatible with the FDA clearance process.

We believe our current facilities are adequate and we have additional

room to expand to meet our manufacturing needs for the foreseeable future.

Research and Development

Our research and development efforts focus on maintaining our advantage

in single molecule sequencing.

These efforts leverage our team’s involvement and continuing development of the tSMS technology for

over a decade.

The tSMS technology blends a number of scientific disciplines, including optics, micro-fluidics, biochemistry and molecular

biology, systems engineering, and bioinformatics.

Over the years, we have continuously established strong relationships with technology

leaders and leading academic centers that augment and complement our internal research and development efforts.

Some of our research and development accomplishments include:

Production of a second generation tSMS sequencer in benchtop form-factor;

Optimized sample preparation, flow cell and reagent tSMS processes;

Innovated machine-learning methods-based image analysis algorithms;

Co-authored multiple publications in scientific journals;

Received multiple National Institutes of Health grant awards for technology development.

We plan to continue our investment in research and development to enhance

the performance and expand the application base of our current products, and to introduce additional products based on our technology.

In addition, our engineering team will continue their focus on increasing instrument component and system reliability, reducing costs,

and implementing additional system flexibility and versatility through the enhancement of existing products and development of new products.

Given the market opportunity, there are a significant number of competing

companies offering gene sequencing equipment or sequencing kits.

These include Illumina, Inc., Pacific Biosciences of California, Inc.,

Thermo Fisher Scientific, Inc., Singular Genomics System, Inc., Element Biosciences, Inc., Ultima Genomics, Inc., and Oxford Nanopore

Technologies, Ltd.

We believe we are uniquely positioned among the competition to be the only company offering high strand throughput

with the power of single molecule resolution.

Our competitors have greater financial, technical, research and/or

other resources than we do.

These companies also have larger and more established manufacturing capabilities and marketing, sales and

support functions.

We expect the competition to intensify within this market.

The increased competition may result in pricing pressures,

which could harm our sales, profitability or market share.

In order for us to successfully compete against these companies, we will need

to demonstrate that our products deliver superior performance and value.

We will also need to continually improve the breadth and depth

of current and future products and applications.

Intellectual Property

Developing and maintaining a strong intellectual property position

is an important element of our business.

We maintain the intellectual property through a combination of licenses, patent protection and

trade secrets.

We have sought, and will continue to seek, patent protection for our

technology, for improvements to our technology, as well as for any of our other technologies for which we believe such protection will

be advantageous.

In 2013, as part of the Helicos bankruptcy proceedings, we entered into the following non-exclusive license agreements:

License Agreement with Helicos Biosciences Corporation.

tSMS technology has been in development since 2004 at Helicos Biosciences Corporation (“Helicos”), which pioneered the first

generation tSMS technology resulting in its commercialization as the HeliScope Genetic Analysis System.

In 2013, Daniel Jones, a former

scientist at Helicos and our current Chief Executive Officer, formed our company to further the development of tSMS.

We then purchased

much of our physical assets from Helicos, including, among other items, sequencers, laboratory equipment, internal servers, protocols

and data analysis procedures, through Helicos’ bankruptcy proceedings that began in 2012.

In 2013, we entered into, and since such date fully paid for, a non-exclusive,

royalty-free license from Helicos, for the life of such patents, for over 60 patents, all but eight of which have since expired or

been abandoned, covering key areas of our technology, including design, methods and chemistry.

As part of the Helicos bankruptcy proceedings,

Fluidigm Corporation, a U.S.

public company engaged in the design, manufacture and sale of biological research equipment based on integrated

fluid circuit technology, obtained the rights to this patent portfolio.

The license grants to us the right to use or sell throughout the

world products or processes based upon the intellectual property covered by the licensed patents in the field of contract gene sequencing,

and prohibits us from sublicensing the intellectual property to any third party or to make any assignment of the license.

may be terminated by Fluidigm in the event we sub-license or assign any of the intellectual to a third party;

however, we have the right

to use the patented technology in connection with any partnership or collaboration in which we have at least a 50% ownership interest.

In addition, Fluidigm has a right to terminate the license in the event Daniel Jones, our Chief Executive Officer, fails to continue to

work full time for us or if we fail to use reasonable care in the investigation, testing or solicitation of government approvals with

respect to the intellectual property.

In addition, the license will automatically terminate in the event we dissolve, cease to conduct

business, file a petition for bankruptcy, assign all of our assets to a receiver or trustee or in the event we have an involuntary bankruptcy

petition initiated against us that is not dismissed within 60 days.

This license is provided to us on an “as is” basis only

and without any representations or warranties, express or implied, regarding the intellectual property and the use thereof.

Fluidigm has no obligation under the license agreement to prosecute any patent application or to maintain any rights to the intellectual

property by payment of any fees to any governmental agency.

While the remaining patents comprising this patent portfolio are expected

to expire in 2025 through 2028, as this patent portfolio has been broadly licensed, we do not expect such expirations to have a material

adverse effect upon our business operations.

Sub-License Agreement with Helicos Biosciences Corporation.

part of the Helicos bankruptcy proceeding, Arizona Science and Technology Enterprises LLC (“AzTE”) agreed that Helicos could

sub-license to us the license agreement between Helicos and AzTE with respect to 10 patents owned by AzTE for the life of such patents.

All of the patents under this sublicense have since expired.

We have one pending patent applications filed in 2021.

a Notice of Allowance regarding our previous patent application 15/754.222.

In October 2022, the USPTO notified us that the related patent

term adjustment was 779 days.

Our issued and pending patents cover various aspects of our sequencing technology, and we expect to continue

to file new patent applications to protect the improvements to our technologies.

We have registered our corporate name (SeqLL) and design logo, as well

as the phrase “tSMS” and “DRS”.

We protect trade secrets, know-how, copyrights, and trademarks, as well as continuing

technological innovation and licensing opportunities to develop and maintain our competitive position.

Our success depends in part on

obtaining patent protection for our products and processes, preserving trade secrets, patents, copyrights and trademarks, operating without

infringing the proprietary rights of third parties, and acquiring licenses for technology or products.

As of December

31, 2023, we had seven employees.

None of our employees are represented by a collective bargaining agreement, and we have never experienced

any work stoppage.

We believe we have good relations with our employees.

Properties and Facilities

On February 2, 2022, we entered into a lease agreement for approximately

15,538 square feet of corporate office and laboratory space in Billerica, Massachusetts.

The lease has a term of 92 months with the rent

escalating from $14,317 to $26,453 per month over the lease term.

Legal Proceedings

From time to time, we may be involved in various disputes and litigation

matters that arise in the ordinary course of business.

We are currently not a party to any material legal proceedings.

Proposed Merger with Lyneer Investments LLC

We have entered into an Agreement and Plan of Reorganization dated

May 29, 2023, as amended, pursuant to which our wholly-owned subsidiary, SeqLL Merger LLC (“SeqLL Merger Sub”),

will merge (the “Merger”) with and into Lyneer Investments LLC (“Lyneer”), with Lyneer continuing as our wholly-owned subsidiary.

In connection with the consummation of the Merger, we will sell our existing assets, other than cash and cash equivalents, which will

be distributed to our pre-Merger stockholders in connection with the Merger, to a newly-formed company owned by our current

employees and management, for nominal consideration, and our continuing business operations will be those of Lyneer.

Lyneer, through its operating subsidiaries, primarily Lyneer Staffing

Solutions, is a national strategic staffing firm servicing the commercial, professional, finance, direct placement, and managed service

provider verticals.

The firm was formed under the principles of honesty and integrity, and with the view of becoming the preferred outside

employer of choice.

Since its formation in 1995, Lyneer has grown from a regional operation to a national staffing firm with offices and

geographic reach across the United States.

Lyneer’s management believes, based on their knowledge of the

industry, that Lyneer is one of the prominent and leading staffing firms in the ever-evolving staffing industry.

Lyneer, headquartered

in Lawrenceville, New Jersey, has over 100 total locations and approximately 300 internal employees.

Its management also believes

that Lyneer is an industry leader in permanent, temporary and temp-to-perm placement services in a wide variety of areas, including,

but not limited to, accounting & finance, administrative & clerical, hospitality, IT, legal, light industrial and medical

Its deep expertise and extensive experience have helped world class companies revolutionize their operations, resulting in greater

efficiency and streamlined processes.

Its comprehensive suite of solutions covers all aspects of workforce management, from recruitment

and hiring to time and attendance tracking, scheduling, performance management, and predictive analytics.

Lyneer takes a personalized

approach to each client, working closely with them to understand their unique needs and develop a tailored roadmap for success.

Lyneer offers a comprehensive range of recruiting services, including temporary and permanent staffing, within the light industrial, administrative,

and financial sectors.

Its services are designed to meet each client’s needs, including payroll services and vendor management services/managed

service provider solutions.

Its extensive network of offices and onsite operations provide local support for its clients, while its national

presence gives Lyneer the resources to tackle even the most complex staffing needs.

With a focus on integrity, transparency and customer

service and a commitment to results, we believe Lyneer has earned a reputation as one of the premier workforce solutions partners in the

United States.

Atlantic was formed in Delaware on October 6, 2022 as a special purpose vehicle to acquire control of a publicly-traded company.

On June 18, 2024 Atlantic completed the acquisition (the “Merger”) of Lyneer Investments LLC and its operating subsidiaries, including Lyneer Staffing Solutions, LLC (collectively, “Lyneer”) and its business operations, which became the principal business operations of our company.

The management team of Atlantic has over 150 combined years of specific corporate management and investment banking experience.

Atlantic’s management has developed long-standing relationships in the institutional investment arena to raise capital for publicly-listed entities to expand and up-list to a national securities exchange.

This has, in turn, created liquidity and higher valuations for these previous companies.

On the Merger date, our corporate headquarters became located at 270 Sylvan Avenue, Suite 2230, Englewood Cliffs, New Jersey 07632.

Our main telephone number at that address will be (201) 899-4470, and our website address is www.atlantic-internationl.com.

Business Model and Acquisition Strategy

Atlantic Acquisition Corp.

(“Atlantic”) was formed in Delaware

on October 6, 2022 as a special purpose vehicle to acquire control of a public company such as our company.

The management team of

Atlantic, which will become the management of our company upon consummation of the Merger, has over 150 combined years of specific

corporate management and investment banking experience.

Atlantic’s business strategy for our company is based upon Lyneer

being a high-growth U.S.-based outsourced services and workforce solutions company with management who have a more than 25-year operating

Based on their knowledge of the industry, Atlantic’s management believes that through their mergers and acquisitions strategy,

they can build our company into a global staffing organization that redefines the way companies grow professional teams.

Its mission is

to leverage new technologies and business partnerships to create streamlined hiring processes that resolve the challenges of modern day

employment economics.

Accordingly, Atlantic’s management is actively engaged in discussions and negotiations with multiple acquisition

targets that complement Atlantic’s core business strategy.

In addition, following the Merger, our strategic direction will be enhanced

by a program that will extend Lyneer’s breadth of services to its broad national reach in a number of complementary areas.

has identified and is focusing on a number of high-demand fields, in particular, the medical, legal and financial services fields.

Atlantic is in the process of investigating a number of opportunities for acquisitions by us of staffing companies that operate in these

identified sectors.

Atlantic’s corporate acquisition strategy is premised on the

seamless consolidation and integration of technology and back-office infrastructure, coupled with performance improvements and value

Its core thesis is designed to allow us to assist our client companies in the transformation of stagnation into growth to achieve

sustainable results through their most important asset:

Atlantic’s goal is to create for us a business designed to deliver

to our clients targeted industry talent at speed and scale while also growing the pool of in-demand talent for this same constituency.

Lyneer’s recruiters will provide specific and data-driven guidance, development, training, and access to jobs.

Atlantic believes

this approach is particularly applicable in several growth sectors, including legal and financial services, technology, and healthcare.

The current climate of industry fragmentation and overall economic uncertainty create a moment that Atlantic believes is ripe for strategic

consolidation.

After the closing of the Merger, Atlantic intends to cause us to aggressively engage in this “M&A” strategy

and to take advantage of the synergies and opportunities created by this congruence of events.

By advantageously augmenting Lyneer’s

existing significant capabilities through acquisition, Atlantic believes we will be able to create material margin improvement.

Atlantic currently has a robust pipeline of potential acquisition targets

for our company and is in negotiations and discussions with outsourced services and workforce solutions acquisition targets in key service

Management of Atlantic believes that multiple targets in the $100,000,000 revenue range are readily available for acquisition

by us within a short period of time.

However, Atlantic does not currently have any binding agreements, arrangements or understandings

concerning any potential acquisition.

By implementing Atlantic’s detailed acquisition strategy, Atlantic’s

management believes we will be able to rapidly accelerate the growth of our company, thus increasing and maximizing shareholder value.

Atlantic’s management plans to pursue “cornerstone acquisitions” focusing on targets with robust profits, diverse client

bases, large national/large regional coverage in contract/permanent staffing, executive search, recruitment process, and outsourcing.

In order to meet such management’s “cornerstone acquisition” criterion, a company should have over $50,000,000 in revenue

and EBITDA margins of no less than 10%.

In addition, Atlantic’s management plans to pursue “tuck-in” acquisitions with

a focus on acquiring high-margin niche staffing companies that can benefit from the synergies of a larger organization with increased

Under its “tuck-in” program, Atlantic’s management intends to acquire smaller profitable companies in business

segments consistent with its larger anchor organizations.

Post-Merger, Atlantic’s management plans to integrate companies

and maximize synergies and economics to improve our sales and lower operating costs, while, at the same time, continuing to focus and

expand on its acquisition strategy of high-margin profitable outsourced services and workforce solution providers.

On May 29, 2023, we, SeqLL Merger Sub, Atlantic, Atlantic Merger

LLC, a Delaware limited liability company and a majority-owned subsidiary of Atlantic (“Atlantic Merger Sub”), Lyneer,

IDC Technologies, Inc., a California corporation (“IDC”), and Lyneer Management Holdings LLC, a Delaware limited liability

company (“Lyneer Management”), entered into an Agreement and Plan of Reorganization (as amended, the “Merger Agreement”),

pursuant to which (i) Atlantic Merger Sub will be merged with and into Lyneer, with Lyneer continuing as the surviving entity and

as an approximately 44%-owned subsidiary of Atlantic, an approximately 50%-owned subsidiary of IDC, and an approximately 6%-owned subsidiary

of Lyneer Management (the “Lyneer Merger”), and (ii) SeqLL Merger Sub will subsequently be merged with and into Lyneer,

with Lyneer continuing as the surviving entity and as our wholly-owned subsidiary (the “SeqLL Merger”).

Lyneer, IDC and

Atlantic are collectively referred to herein as the “Sellers.”

We currently expect the Merger to be consummated in the second quarter

of 2024, subject to the satisfaction of certain closing conditions, including our consummation of a public offering of our equity securities

in which we receive gross proceeds of $20 million (the “Public Offering”), of which there can be no assurance.

At the effective

time of the Merger, in consideration of 100% of the membership interests of Lyneer, we will (i) pay to IDC and Lyneer Management

an aggregate of $16,250,000 in cash (the “Cash Consideration”), (ii) issue to (a) IDC and Lyneer Management an aggregate

of 5,500,000 shares of our common stock and (b) to Atlantic 300,000 shares of our common stock, in each case assuming a public offering

price of $10.00 per Unit in this Public Offering (the “Stock Consideration”), and (iii) issue to IDC a convertible promissory

note (the “Merger Note,” and collectively with the Cash Consideration and the Stock Consideration, the “Merger Consideration”)

in the principal amount of $18,750,000 that will mature on July 31, 2024.

The Merger Note will not bear interest and will not be

convertible prior to an event of default under the Merger Note.

If an event of default should occur under the Merger Note, the Merger

Note will bear interest at the rate of 7% per annum commencing upon the date of such event of default and will be convertible into shares

of our common stock at a price per share that equals then-current market prices, but not less than 80% of the price per share at

which our common stock is sold in the Public Offering.

If the Merger Note is converted into shares of our common stock, IDC will have

demand and incidental registration rights with respect to such shares.

We believe we will have to sell additional equity or debt securities

prior to the maturity date of the Merger Note to pay or refinance the Merger Note when due.

The Merger Agreement contains customary representations and warranties

from the parties, and each party has agreed to customary covenants applicable to such party, including, among others, covenants relating

to (i) the conduct of their respective businesses in the ordinary course prior to the effective time of the Merger and (ii) the

requirement of each party to maintain and preserve intact their respective business organizations, assets, properties and material business

Pursuant to the Merger Agreement as originally executed, we were also required, prior to the closing of the Merger, to declare

a cash dividend payable to our stockholders of record as of the close of business on September 26, 2023, in an amount equal our cash and

cash equivalents as of the closing date of the Merger, less any amounts withheld for taxes and certain other obligations as of such date.

Concurrently with the declaration of such cash dividend, we were also required to declare a stock dividend issuable to such stockholders

of an aggregate of number of shares of our common stock that, when added to such value of the outstanding shares of common stock

on September 26, 2023, in each case valued at the price per share at which our common stock is sold in the Public Offering, will equal

However, on November 3, 2023, the parties to the Merger Agreement amended the Merger Agreement to delete the requirement

for the declaration of such dividends in consideration of our agreement to make a settlement offer within 90 days of the closing of the

Merger to our stockholders of record as of the close of business on September 26, 2023 to settle any claims for failing to pay such dividends

by issuing to such stockholders the amount of cash and the number of shares of our common stock that such stockholders would have received

had such dividends been declared and made.

In connection with the execution and delivery of the Merger Agreement,

we entered into the Asset Purchase Agreement with SeqLL Omics.

SeqLL Omics was recently formed by Daniel Jones, our current Chairman of

the Board and Chief Executive Officer, and certain other employees of our company, for the purpose of carrying on our pre-Merger business

after the Merger.

Subject to the terms and conditions of the Asset Purchase Agreement, SeqLL Omics has agreed to purchase from us, and

we have agreed to sell to SeqLL Omics, for a purchase price of $1,000, all of our rights and interest in our assets and properties as

they exist immediately prior to consummation of the Merger, excluding cash and cash equivalents.

In negotiating the Merger Agreement with

Atlantic, it was a requirement of Atlantic that at the closing of the Merger, we will have disposed of our pre-Merger business operations,

including all or substantially all of our assets, and will have transferred or satisfied all of our pre-Merger liabilities, other

than those pre-Merger liabilities that we have expressly agreed to retain pursuant to the Merger Agreement.

Summary of Risk Factors Related to Lyneer

Lyneer’s business is subject to numerous risks and uncertainties

that could affect our business and our company following consummation of the Merger.

The significant risks include, but are not limited

to, the following:

● Lyneer’s history of losses may harm our ability to

obtain additional financing;

● Lyneer’s ability to restructure its existing debt obligations

and to eliminate existing joint and several liability with its current parent company, IDC;

● following the consummation of the Merger, a default by Lyneer

on its existing credit facilities could result in foreclosure on IDC’s controlling ownership interest in our company and foreclosure

on our ownership of the equity securities of Lyneer;

● Lyneer’s ability to retain its largest clients;

● Lyneer’s ability to integrate the combined operations

of our previously-acquired companies;

● our ability to make future acquisitions following the Merger,

and effectively integrate any future combined operations;

● general economic conditions in the United States;

● our ability to achieve and maintain profitability following

● our ability to sustain or grow our customer base for Lyneer’s

current services and provide superior customer service;

● our liquidity and working capital requirements following

the Merger, including our cash requirements over the next 12 months;

● our ability to relist our securities on the Nasdaq Capital

Market following the Merger and to satisfy and maintain the ongoing listing requirements for the Nasdaq Capital Market;

● compliance with the U.S.

regulations applicable to our

● our ability to implement Atlantic’s roll-up strategy

and future plans of operations;

● expectations regarding the size of Lyneer’s market;

● our expectations following the Merger regarding the future

market demand for our services;

● compliance with applicable laws and regulatory changes;

● our ability to identify, attract and retain qualified personnel

and the loss of key personnel;

● the limitation of liability and indemnification of our officers

and directors following the Merger;

● economic conditions affecting the staffing industry in which

Lyneer operates;

● maintaining Lyneer’s intellectual property rights and

any potential litigation involving intellectual property rights;

● our ability following the Merger to anticipate and adapt

to a developing market(s) and to technological changes;

● following the Merger, acceptance by customers of any new

● a competitive environment characterized by numerous, well-established and

well-capitalized competitors;

● the ability to develop and upgrade our technology and information

systems and keep up with rapidly evolving industry standards;

● any interruption in the supply of services;

● discontinuance of support for our information systems from

third party vendors;

● significant fluctuations in Lyneer’s quarterly operating

● following the Merger, the extent, liquidity, volatility and

duration of any public trading market for our securities;

● the resale of our securities following the Merger could adversely

affect the market price of our common stock and our ability to raise additional equity capital;

● we may become subject to “penny stock” rules,

which could damage our reputation and the ability of investors to sell their shares;

● following the Merger, insiders, including significant stockholders,

will continue to have substantial control over our company.

Unless the Merger Agreement has been terminated, Investors should consider

the risks and uncertainties relating to the Merger and Lyneer summarized above, as well as the more detailed discussion of such risks

and uncertainties included in our in our registration statement on Form S-1 (Registration No.

333-272908) filed with the SEC, a copy of

which is publicly available through the SEC’s website at http://www.sec.gov .

Additional risks relating to Lyneer not

presently known to us or that we currently deem immaterial may also affect us following consummation of the Merger.

If, following the

Merger, any of these risks occur, our business, financial condition, or results of operations could be materially and adversely affected.

Atlantic is a high-growth U.S.-based outsourced services and workforce solutions company with management who have a more than 25-year operating record.

Based on their knowledge of the industry, Atlantic’s management believes that through its mergers and acquisitions strategy, Atlantic expects to build a global staffing organization that redefines the way companies grow professional teams.

Its mission is to leverage new technologies and business partnerships to create streamlined hiring processes that resolve the challenges of modern-day employment economics.

Accordingly, Atlantic is actively engaged in discussions and negotiations with multiple acquisition targets that complement Atlantic’s core business strategy.

In addition, Atlantic’s strategic direction will be enhanced by a program that will extend Lyneer’s breadth of services to its broad national reach in a number of complementary areas.

Atlantic has identified and is focusing on a number of high-demand fields, in particular, the medical, legal and financial services fields.

Atlantic is in the process of investigating a number of opportunities for acquisitions of staffing companies that operate in these identified sectors.

Atlantic’s corporate acquisition strategy is premised on the seamless consolidation and integration of technology and back-office infrastructure, coupled with performance improvements and value creation.

Its core thesis is designed to assist its client companies in the transformation of stagnation into growth to achieve sustainable results through their most important asset:

Atlantic’s goal is to create a business designed to deliver to its clients targeted industry talent at speed and scale while also growing the pool of in-demand talent for this same constituency.

Atlantic’s recruiters will provide specific and data-driven guidance, development, training, and access to jobs.

It believes this approach is particularly applicable in several growth sectors, including legal and financial services, technology, and healthcare.

The current climate of industry fragmentation and overall economic uncertainty create a moment that Atlantic believes is ripe for strategic consolidation.

Atlantic intends to aggressively engage in this “M&A” strategy and to take advantage of the synergies and opportunities created by this congruence of events.

By advantageously augmenting Lyneer’s existing significant capabilities through acquisition, Atlantic believes Lyneer will create material margin improvement.

Moreover, Atlantic has commenced implementation of a detailed acquisition strategy that it believes will rapidly accelerate its growth, thus increasing and maximizing shareholder value.

Atlantic plans to pursue “cornerstone acquisitions” and is focusing on targets with robust profits, diverse client bases, large national/large regional coverage in contract/permanent staffing, executive search, recruitment process, and outsourcing.

In order to meet its “cornerstone acquisition” criterion, a company is expected to have over $50,000,000 in revenue and EBITDA margins of no less than 10%.

In addition, Atlantic plans to pursue “tuck-in” acquisitions with a focus on acquiring high-margin niche staffing companies that can benefit from the synergies of a larger organization with increased penetration.

Under its “tuck-in” program, Atlantic intends to acquire smaller profitable companies in business segments consistent with its larger anchor organizations.

Atlantic plans to integrate companies and maximize synergies and economics to improve sales and lower operating costs, while, at the same time, continuing to focus and expand on its acquisition strategy of high-margin profitable outsourced services and workforce solution providers.

Atlantic currently is in discussions and negotiations with multiple prospects and any such acquisitions are subject to the completion of due diligence and the negotiation and execution of final agreements.

These prospects are representative of the types of companies and verticals that Atlantic is actively pursuing and underscore the opportunity for Atlantic to expand its footprint in lucrative markets with great demand for professionals and skilled workforce.

Atlantic believes that the need for these services in these markets is becoming acute.

Atlantic also believes that it is well positioned to execute on its acquisition plan.

Should the proposed acquisitions be consummated, Atlantic will greatly increase its capabilities in the prime financial services and thriving healthcare support services vertical.

Staffing 360 Acquisition

On November 1, 2024, as amended on January 7, 2025, Atlantic, Staffing 360 Solutions, Inc.

a Delaware corporation (“STAF”), and A36 Merger Sub Inc., a Delaware corporation and a wholly-owned subsidiary of the Company entered into an Agreement and Plan of Merger (the “Staffing 360 Merger Agreement”), pursuant to which Merger Sub would merge with and into STAF, with STAF surviving as a wholly-owned subsidiary of the Company (the “Staffing 360 Merger”).

Subject to the terms and conditions of the Staffing 360 Merger Agreement, upon completion of the Staffing 360 Merger, Atlantic would acquire all outstanding shares of STAF’s common stock.

On February 26, 2025, Atlantic sent a notice of termination to STAF pursuant to the terms and conditions of the Staffing 360 Merger Agreement.

The Staffing 360 Merger agreement required STAF to execute and/or deliver:

“a signed agreement between the Internal Revenue Service and Company [i.e., STAF] concerning the terms of settlement mutually agreeable to Atlantic ” (Emphasis Added).

Without the Company’s knowledge, STAF entered into agreements with the Internal Revenue Service that were not agreeable to Atlantic.

STAF materially failed to satisfy the terms of the Staffing 360 Merger Agreement and has done so in a manner that cannot be cured.

Accordingly, this was a material breach of the covenant and agreement set forth in the Staffing 360 Merger Agreement to deliver:

“a signed agreement between the Internal Revenue Service and Company (i.e., STAF) concerning the terms of settlement mutually agreeable to Atlantic.”

Finally, STAF has failed to demonstrate compliance under the Staffing 360 Merger Agreement, namely to (i) operate the Business in the ordinary course in all material respects and (ii) use commercially reasonable efforts to preserve intact the business organization, assets, properties and material business relations of STAF, both as reflected by STAF’s failure to satisfy its obligations and maintain its material business relations, among other reasons.

Lyneer, through its operating subsidiaries, primarily Lyneer Staffing Solutions, is a national strategic staffing firm servicing the commercial, professional, finance, direct placement, and managed service provider verticals.

The firm was formed under the principles of honesty and integrity, and with the view of becoming the preferred outside employer of choice.

Since its formation in Lyneer has grown from a regional operation to a national staffing firm with offices and geographic reach across the United States.

Lyneer’s management believes, based on their knowledge of the industry, that Lyneer is one of the prominent and leading staffing firms in the ever-evolving staffing industry.

Lyneer, headquartered in Lawrenceville, New Jersey, has over 100 total locations and approximately 300 internal employees.

Its management also believes that Lyneer is an industry leader in permanent, temporary and temp-to-perm placement services in a wide variety of areas, including, but not limited to, accounting & finance, administrative & clerical, hospitality, IT, legal, light industrial and medical fields.

Its deep expertise and extensive experience have helped world class companies revolutionize their operations, resulting in greater efficiency and streamlined processes.

Its comprehensive suite of solutions covers all aspects of workforce management, from recruitment and hiring to time and attendance tracking, scheduling, performance management, and predictive analytics.

Lyneer takes a personalized approach to each client, working closely with them to understand their unique needs and develop a tailored roadmap for success.

In addition, Lyneer offers a comprehensive range of recruiting services, including temporary and permanent staffing, within the light industrial, administrative, and financial sectors.

Its services are designed to meet each client’s needs, including payroll services and vendor management services/managed service provider solutions.

Its extensive network of offices and onsite operations provide local support for its clients, while its national presence gives Lyneer the resources to tackle even the most complex staffing needs.

With a focus on integrity, transparency and customer service and a commitment to results over a 25-year period, management believes Lyneer has earned a reputation as one of the premier workforce solutions partners in the United States.

National Presence

Nation-wide Support

Lyneer By the Numbers:

Employees Annually

1,200+ (and growing)

25+ years of industry experience

At Lyneer, management understands that finding the perfect candidate starts before the job requisition even comes in.

Lyneer employs the strategy of proactive recruitment to build a pipeline of pre-vetted candidates for order fulfilment.

Lyneer’s client mix consists of both small- and medium-size businesses, and large national and multinational client relationships.

Client relationships with small- and medium-size businesses are based on a local or regional relationship, and tend to rely less on longer-term contracts, and the competitors for this business are primarily locally owned businesses.

Comprising over 60% of Lyneer’s revenue base, the large national and multinational clients, on the other hand, will frequently enter into non-exclusive arrangements with several firms, with the ultimate choice among them being left to local managers.

As a result, employment services firms with a large network of offices compete most effectively for this business, which generally has agreed-upon pricing or mark-up on services performed.

Lyneer Service Offerings

Lyneer’s client contracts can be highly customized and generally provide for hiring, administration and benefit services.

The contracts are typically for a term of one to two years and are automatically renewable;

however, the client may terminate the agreement for convenience at any time, subject to any accrued payment obligations.

The contracts also typically provide the candidate attributes necessary for a successful candidate.

Lyneer’s client contracts generally include standard payment terms that are acceptable in each of the states and cities in which Lyneer operates.

The payment terms vary by the type and location of Lyneer’s clients and the services offered.

While all customers are invoiced weekly and payment terms vary, the majority of Lyneer’s customers have payment terms of 30 days;

however the Company may extend to 150 days from the invoice date.

Customers are assessed for credit worthiness at the commencement of an engagement through a credit review, which is considered in establishing credit terms for individual customers.

Revenues that have been recognized but not invoiced for temporary staffing customers are included in “unbilled accounts receivable” on Lyneer’s consolidated balance sheets and represent a contract asset under ASC 606.

Terms of collection vary based on the customer;

however payment generally is due within 30 days.

Temporary Placement

This model offers staffing services in its most basic form while providing Lyneer’s clients with the in-depth knowledge Lyneer brings to the process and its deep breath of candidates.

These engagements are usually definitive in time and generally do not exceed a year in engagement.

Lyneer invoices its clients for temporary placement services concurrently with each periodic payroll that coincides with the services provided.

Most engagement professionals placed on assignment by Lyneer are actually Lyneer’s employees while they are working on assignments.

Lyneer pays all related costs of employment, including workers’ compensation insurance, state and federal unemployment taxes, social security, and certain fringe benefits that are part of the costs model billed to the clients.

Direct Hire & Permanent Placement

Direct hire and permanent placement services are traditional workplace placement services through which Lyneer seeks qualified candidates to help a client grow its permanent staff.

Permanent placement contracts with customers are primarily recognized when employment candidates accept offers of permanent employment and begin work for Lyneer’s customers.

Certain of Lyneer’s permanent placement contracts contain a 30-day guarantee period in which the client can “test drive” the candidate in order to insure a “good fit.” In the event a candidate voluntarily leaves or is terminated for cause prior to the completion of 30 days of employment, Lyneer will provide a replacement candidate at no additional cost, as long as the placement fee is paid within 30 days of the candidate’s start date.

Fees to clients are generally calculated as a percentage of the new employee’s annual compensation.

No fees for permanent placement talent solutions services are charged to employment candidates, regardless of whether the candidate is placed.

Vendor Management Services and Managed Service Provider Support

Lyneer’s managed service programs have a track record of success supporting large-scale vendor management services programs.

Lyneer’s managed services programs combine advanced technology, deep functional and sector expertise, and operational excellence for knowledge-intensive processes across the client’s enterprise.

Lyneer offers the services in various packages — with predictable costs, any-shore delivery, and the option to flex up or down to meet fast-changing needs.

Verticals That Lyneer Services

Lyneer’s team represents a broad range of skilled professional candidates that Lyneer can call upon to fill the needs of its clients.

Lyneer’s recruiters use their years of experience, instinct and industry expertise to make sure the correct candidate is selected for the right position.

Lyneer acts as a trusted consultant assisting with recruiting, screening and placing candidates and then monitoring their progress and the client’s satisfaction to ensure that the candidates perform at the highest level.

In particular, Lyneer’s expertise extends in the following verticals:

• Accounting & Finance — Accountants, controllers, accounts receivables, accounts payables, accounting clerks, audit

• Customer Service — Call centers, customer service representatives, retail, marketing, product development

• Hospitality — Room attendants, bartenders, housekeepers, front end services, food attendants, service

• Professional & Medical — Legal professionals, attorneys, paralegals, lab technicians, phlebotomists

• Light Industrial — Warehouse, pick/pack, distribution, manufacturing, packaging, retail setup, retail support services, mail sort and distribution

With an expansive database that is revitalized by its clients daily, Lyneer effectively evaluates its candidates’ skills to make the right match for the client and the candidate.

Lyneer acts as a consultant;

Lyneer’s experienced recruiters provide resume editing, career counselling and interview preparation to make a candidate stand out.

Lyneer knows its clients’ needs and its candidates’ capabilities and therefore attempts to find solutions that work.

Lyneer’s Competitive Advantages

Lyneer’s management believes that Lyneer has the following competitive advantages (see “Atlantic Business Model and Acquisitions Strategy”):

• Industry Leading Management — Assembled management expertise across all company disciplines and offerings consisting of established industry leaders, as well as business founders.

• Integrated Services — An integrated business model allows our business systems to enable a holistic view of our client, its data, and the organizational health.

It creates a better customer experience and improves internal workflow.

• Category Experience — Accounting & finance, administrative & clerical, hospitality, IT, legal, light industrial and medical fields.

• Results Driven — Each of Lyneer’s staffing experts is specially trained to unite the right talent with the right position creating a mutually beneficial relationship between client and employee.

• One Stop Comprehensive Outsourced Services and Workforce Solution Support Model — Lyneer’s extensive network of offices and onsite operations provide local support for its clients, while its national presence gives us the resources to tackle even the most complex staffing needs.

• Client Base — Blue-chip clients with long-term relationships with Lyneer.

Market Conditions and Opportunity

Start-up costs for an outsourced services and workforce solutions company are very low.

Individual offices can be profitable, but consolidation is driven mainly by the opportunity for large agencies to develop national relationships with big customers.

Some agencies expand by starting new offices in promising markets, but most prefer to buy existing independent offices with proven staff and an existing customer roster.

Temporary workers have become such a large part of the workforce that staffing company employees often work at the customer’s site to recruit, train, and manage temporary employees.

Lyneer has a number of onsite relationships with its customers.

Staffing companies try to match the best qualified employees for the customer’s needs, but often provide additional training specific to that company, such as instruction in the use of proprietary software.

Some personnel consulting firms and human resource departments are increasingly using psychological tests to evaluate potential job candidates.

Psychological or liability testing has gained popularity, in part, due to recent fraud scandals.

In addition to stiffer background checks, headhunters often check the credit history of prospective employees.

Lyneer’s management believes the trends of outsourcing entire departments and dependence on temporary and leased workers will expand opportunities for outsourced services companies.

Taking advantage of their expertise in assessing worker capabilities, some companies manage their clients’ entire human resource functions.

Human resources outsourcing may include management of payroll, tax filings, and benefit administration services.

Human resources outsourcing may also include recruitment process outsourcing, whereby an agency manages all recruitment activities for a client.

New online technology is improving staffing efficiency.

For example, some online applications coordinate workflow for staffing agencies, their clients and temporary workers, and allow agencies and customers to share work order requests, submit and track candidates, approve timesheets and expenses, and run reports.

Interaction between candidates and potential employers is increasingly being handled online.

Initially viewed as rivals, some Internet job-search companies and traditional employment agencies are now collaborating.

While some Internet sites do not allow agencies to use their services to post jobs or look through resumes, others find that agencies are their biggest customers, earning the sites a large percentage of their revenue.

Some staffing companies contract to help client employers find workers online.

Additionally, data supports the growing need for services in the key verticals Lyneer has identified:

Bureau of Labor Statistics anticipates approximately 6% growth yearly and about 9,600 open positions annually through 2031 as is the demand for licensed and vocational nurses.

• The Association of American Medical Colleges estimates that the country’s rapidly-increasing demand for physicians over the next 15 years will outpace its supply, leading to a shortage of between 37,800 and 124,000 physicians by 2034, according to the report, The Complexities of Physician Supply and Demand:

Projections from 2019-2034.

That shortage includes shortfalls of 17,800 to 48,000 primary care physicians and 21,000 to 77,100 specialists.

• According to the Massachusetts Medical Society, there are renewing concerns about the stability of the state’s health care workforce.

More than half of the almost 600 doctors surveyed said they had already cut back on time with patients — or were likely to do so.

Other jurisdictions face similar dilemmas.

• In a 2021 report by Thomson Reuters, the use of Alternative Legal Service Providers (ALSPs) in the United States showed a high market penetration with E-Discovery being the dominant service sought by law firms.

According to the report, the alternative legal service providers market is currently valued at $14 billion.

• According to a 2022 survey from Deloitte, 82.4% of hiring managers for accounting and financial roles at public companies admit to struggling with talent retention, and 68.9% of hiring managers at private companies say the same, thus creating a need to work hard to attract and retain top talent.

Scalable Model to Fit Business Needs

Lyneer’s services can be scaled up or down to meet the needs of medium and large clients or clients with disparate locations.

Staffing & Recruitment — A consistent team effort to support the forecasts of Lyneer’s clients and meet their staffing needs.

Program Management — Lyneer manages its program with individual clients to meet the client’s business needs and manages and maintains such a detailed program on an ongoing basis with the client and closely monitored by staff throughout the entirety of the business relationship.

Data Management — Lyneer implements custom database solutions for each client, which helps it track usage throughout the entirety of the business platform and other critical variables.

Continuous Improvement — Lyneer maintains consistent lanes of open communication with clients and stakeholders.

Lyneer’s continual maintenance of client relationships allows Lyneer to better understand the needs of its client partners and also increases workplace productivity.

Technology Leveraging — Lyneer utilizes the latest technology to leverage its services, including artificial intelligence (“AI”), which is providing companies with an efficient way to reduce the time they spend on the recruitment process while still ensuring that they hire quality candidates.

AI and other technologies help reduce recruitment times by leveraging automation for certain aspects of the job search process.

Lyneer has one client that represented approximately 16% of both Lyneer’s 2024 and 2023 revenues.

The client’s contract with Lyneer consists of a master service agreement (“MSA”) for temporary employee services with various customer locations entering into separate service annexes.

None of these locations has exceeded 5% of the revenue associated with the client.

The current term of the MSA expires in January 2026 and automatically renews for one-year subsequent terms.

However, the client may terminate the agreement for convenience at any time, subject to any accrued payment obligations.

Lyneer’s workforce solutions business is generally more active in the first and fourth quarters of a calendar year when certain professional services are in greater demand.

Lyneer conducts business under various federal, state, and local government contracts.

One customer comprises 16% of total services revenues in 2024, but that customer has several contracts within federal, state and local governments and no one such contract represented more than 5.0% percent of its total service revenues in 2024.

Lyneer competes in the employment services industry by offering a broad range of services, including permanent, temporary and contract recruitment, project-based workforce solutions, assessment and selection, training, career and talent management, managed service solutions, outsourcing, consulting and professional services.

Lyneer’s industry is large and fragmented, comprised of tens of thousands of firms employing millions of people and generating billions of dollars in annual revenues.

In most areas, no single company has a dominant share of the employment services market.

The largest publicly owned companies specializing in recruitment services are The Adecco Group and Randstad.

Lyneer also competes against a variety of regional or specialized companies such as Recruit Holdings, Allegis Group, Kelly Services, Manpower, Robert Half, Kforce, PageGroup, Korn/Ferry International and Alexander Mann.

It is a highly competitive industry, reflecting several trends in the global marketplace such as the increasing demand for skilled people, employers’ desire for more flexible working models and consolidation among clients and in the employment services industry itself.

Government Regulations

Lyneer’s operations are subject to regulations by various federal, state, local and independent governing bodies, including, but not limited to, (a) licensing and registration requirements and (b) regulation of the employer/employee relationship, such as worker classification regulations (e.g., exempt/non-exempt classifications), wage and hour regulations, tax withholding and reporting, immigration regulations, social security and other retirement, anti-discrimination, and employee benefits and workers’ compensation regulations.

Lyneer’s operations could be impacted by legislative changes by these bodies, particularly with respect to provisions relating to payroll and benefits, tax and accounting, employment,

worker classification and data privacy.

Due to the complex regulatory environment that Lyneer operates in, Lyneer remains focused on compliance with governmental and professional organizations’ regulations.

For more discussion of the potential impact that the regulatory environment could have on its financial results, refer to Item 1A – Risk Factors below for further information.

Lyneer maintains a number of registered trademarks, trade names and service marks in the United States.

Lyneer believes that many of these marks and trade names, including Lyneer Staffing Solutions, Lyneer and Lyneer International have significant value and are materially important to its business.

In addition, Lyneer maintains other intangible property rights.

Lyneer had approximately 300 full-time internal staff as of December 31, 2024.

In addition, Lyneer placed approximately 60,000 engagement professionals and workers (which includes full time engagement professionals) on assignments with clients during 2024.

The substantial majority of engagement professionals placed on assignment by Lyneer are Lyneer’s temporary employees while they are working on assignments.

With respect to engagement professionals, Lyneer pays the related costs of employment, such as workers’ compensation insurance, state and federal unemployment taxes, social security, and certain fringe benefits.

None of Lyneer’s employees is subject to a collective bargaining agreement or an employment agreement other than senior management or as required by applicable law.

As described under Part III, Item 11 — E xecutive Compensation — Employment and Consulting Agreements , certain executives and key employees have executed employment and consulting agreements with Lyneer.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business